Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.65 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28407124 | 0.84 | SLC5A2 (0.77) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17623721 | 0.83 | SLC5A2 (0.76) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1713871 | 0.82 | SLC5A2 (0.75) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL28430017 | 0.80 | SLC5A2 (0.74) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14235806 | 0.79 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL15610397 | 0.79 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL28430019 | 0.79 | SLC5A2 (0.67) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL29637857 | 0.78 | SLC5A2 (0.98) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL29377767 | 0.78 | SLC5A2 (0.98) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14235786 | 0.78 | SLC5A2 (0.77) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140046046-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140046046-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20120296080-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120296080-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| EP-2382972-A1 | Methods for preventing and treating neurodegenerative disorders | Boehringer Ingelheim International GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2360165-A2 | GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2011-08-24 | — | — | EP | disclosed |
| US-20110178033-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-21 | — | — | US | disclosed |
| US-20110178033-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-21 | — | — | US | disclosed |
| EP-2295422-A2 | Glucopyranosyl substituted benzol derivatives, pharmaceutical compositions containing these compounds, use thereof and method for their production | Boehringer Ingelheim International GmbH (DE) | 2011-03-16 | — | — | EP | disclosed |
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20090326215-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326215-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-7579449-B2 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-7579449-B2 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008090210-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885ADRA2A 401/4885 |
| US-20110178033-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, G6PC1 | SLC5A2 7/4885SLC5A1 5/4885ADRA2A 379/4885 |
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | HTT, SNCA, PSEN2 | SLC5A2 59/4885SLC5A1 41/4885ADRA2A 2392/4885 |
| US-20120296080-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, G6PC1 | SLC5A2 7/4885SLC5A1 5/4885ADRA2A 379/4885 |
| US-20140046046-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885ADRA2A 401/4885 |
| US-20090326215-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, G6PC1 | SLC5A2 7/4885SLC5A1 5/4885ADRA2A 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.